Achieve Life Sciences (ACHV) Scheduled to Post Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHVGet Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.79) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHVGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.02. During the same quarter in the prior year, the company earned ($1.30) EPS. On average, analysts expect Achieve Life Sciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Achieve Life Sciences Stock Performance

NASDAQ ACHV opened at $4.97 on Thursday. Achieve Life Sciences has a 52-week low of $4.81 and a 52-week high of $10.09. The company has a debt-to-equity ratio of 0.71, a quick ratio of 9.40 and a current ratio of 9.40. The company has a market capitalization of $48.12 million, a P/E ratio of -1.31 and a beta of 1.19. The company has a fifty day moving average of $5.64 and a 200-day moving average of $6.72.

Analyst Ratings Changes

Separately, Oppenheimer lifted their price objective on shares of Achieve Life Sciences from $23.00 to $27.00 in a report on Wednesday, April 27th.

Hedge Funds Weigh In On Achieve Life Sciences

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. purchased a new position in Achieve Life Sciences in the 1st quarter worth $79,000. Raymond James & Associates purchased a new position in Achieve Life Sciences in the 1st quarter worth $99,000. Finally, State Street Corp raised its position in Achieve Life Sciences by 26.9% in the 1st quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 3,970 shares during the period. Hedge funds and other institutional investors own 37.27% of the company’s stock.

Achieve Life Sciences Company Profile

(Get Rating)

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.

Featured Stories

Earnings History for Achieve Life Sciences (NASDAQ:ACHV)

Want More Great Investing Ideas?

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with's FREE daily email newsletter.